Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. is registering for resale up to 7,650,764 shares of common stock, consisting of 4,501,928 shares of common stock and 3,148,836 shares issuable upon exercise of pre-funded warrants, pursuant to registration rights from a March 9, 2026 private placement. The resale registration covers shares held by the identified selling stockholders and does not mean they will sell all or any of their shares. The company will not receive proceeds from sales by the selling stockholders, though it will receive the nominal exercise price for any exercised pre-funded warrants.
Korro Bio, Inc. reports a Schedule 13G disclosing a group filing by Venrock-related entities and principals regarding beneficial ownership. The Reporting Persons state aggregated holdings tied to pre-funded warrants and common stock that are capped by a "Beneficial Ownership Blocker" preventing exercise above 9.99%.
The filing cites 14,422,571 shares of common stock outstanding as of March 10, 2026 and notes the group is currently capped at beneficial ownership of 1,488,685 shares, representing 9.99% of the class (EDGAR rounding shows 9.9% on cover pages). The group’s positions include stated pre-funded warrants exercisable into additional shares; exercise is restricted to avoid exceeding the ownership blocker.
Korro Bio filed a shelf registration to permit resale of up to 7,650,764 shares of common stock by selling stockholders. The amount comprises 4,501,928 issued common shares and 3,148,836 shares issuable upon exercise of pre-funded warrants under a March 9, 2026 private placement.
The resale is a secondary offering by the selling stockholders; the company states it will not receive proceeds from those resales (other than the $0.001 per-share exercise price if pre-funded warrants are exercised for cash). Percentage ownership in the prospectus is based on 14,422,571 shares outstanding as of March 11, 2026.
Korro Bio, Inc. reported that investment entities associated with Rick Yang made significant indirect open-market purchases of its securities. On March 10, 2026, New Enterprise Associates 17, L.P. acquired 242,945 Pre-Funded Warrants at $11.1090 per warrant and 207,100 shares of Common Stock at $11.1100 per share under a Subscription Agreement dated March 9, 2026. Following these transactions, NEA 17 indirectly holds 1,297,893 shares of Common Stock and the Pre-Funded Warrants, while the Reporting Person disclaims beneficial ownership where there is no pecuniary interest. The Pre-Funded Warrants are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ prior notice.
SANDELL SCOTT D reported open-market purchase transactions in this Form 4 filing.
Korro Bio, Inc. insider entities linked to Scott D. Sandell indirectly acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026, pursuant to a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants carry a $0.001 exercise price and are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ notice.
New Enterprise Associates 17, L.P., a 10% owner of Korro Bio, Inc., bought additional securities in the company. On March 10, 2026, it acquired 207,100 shares of Common Stock at $11.11 per share and 242,945 Pre-Funded Warrants at $11.109 per warrant pursuant to a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants are exercisable at $0.001 per share at any time after issuance but include a beneficial ownership cap that generally limits the holder to 9.99% of Korro Bio’s outstanding Common Stock, which can be adjusted up to 19.99% with 61 days’ prior notice.
Korro Bio, Inc. reported that a 10% owner associated with Carmen Chang made significant indirect open-market purchases of its securities. On March 10, 2026, an entity affiliated with her acquired 242,945 Pre-Funded Warrants at $11.109 per warrant and 207,100 shares of Common Stock at $11.11 per share, totaling 450,045 securities.
The Pre-Funded Warrants were acquired from the company under a Subscription Agreement dated March 9, 2026 and are exercisable at any time, subject to a beneficial ownership cap of 9.99% of outstanding common stock, adjustable up to 19.99% with 61 days’ notice. The transactions are reported as indirect holdings through New Enterprise Associates 17, L.P., and Chang disclaims beneficial ownership of any portion in which she has no pecuniary interest.
Korro Bio, Inc. reported that investment entities associated with director and 10% owner Ali Behbahani acquired additional securities. On March 10, 2026, NEA 17 received 242,945 Pre-Funded Warrants, each exercisable into one share of Common Stock at $0.001 per share, subject to a 9.99% ownership cap that can be raised up to 19.99% with 61 days’ notice. The same day, NEA 17 was also awarded 207,100 shares of Common Stock at $11.11 per share, bringing its indirectly held Common Stock position to 1,297,893 shares. Behbahani is a manager of the NEA 17 general partners and disclaims beneficial ownership of portions in which he has no pecuniary interest.
Korro Bio, Inc. reported that investment entity New Enterprise Associates 17, L.P. acquired additional exposure to its stock through a private subscription. On March 10, 2026, it bought 207,100 shares of common stock at $11.11 per share and 242,945 pre-funded warrants at $11.109 per warrant. The warrants are exercisable at $0.001 per share but include a 9.99% beneficial ownership cap, which the holder may adjust upon 61 days’ notice, not to exceed 19.99%. Following these purchases, indirect holdings include 1,297,893 shares of common stock and the newly acquired warrants. Forest Baskett is a manager of entities controlling NEA 17 and disclaims beneficial ownership where he has no pecuniary interest.